-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascentage Pharma Presents Nine Ongoing Global Registrational Trials in Corporate Overview

PUBT·11/16/2026 15:54:02
Ascentage Pharma Presents Nine Ongoing Global Registrational Trials in Corporate Overview
  • Ascentage Pharma reported $41.6 million in product sales for the first half of 2026 from two marketed products.
  • Cash totaled $279.4 million as of June 30, 2026.
  • Nine global registrational trials are ongoing, including four FDA-cleared Phase III trials.
  • Lisaftoclax's GLORA-4 Phase III trial targets frontline higher-risk MDS, with complete response and overall survival as dual primary endpoints.
  • The China commercial team exceeds 300 employees, with plans to reach about 400 sales representatives covering approximately 80% of prescribers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.